INFI

Infinity Pharmaceuticals, Inc. [INFI] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

INFI Stock Summary

In the News

07:34 29 Mar 2024 INFI

Why Is Infinity Pharmaceuticals (INFI) Stock Up 84% Today?

Infinity Pharmaceuticals (NASDAQ: INFI ) stock is rocketing higher on Tuesday morning despite a lack of news from the biopharmaceutical company. Investors seeking out news concerning shares of INFI stock this morning won't find any new press releases or filings.

12:08 29 Mar 2024 INFI

MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates

SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced today that the companies will host a recorded joint video webcast that will be available at 8:00 am Eastern.

07:04 29 Mar 2024 INFI

Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Lags Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of 8.33% and 95.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

11:29 29 Mar 2024 INFI

Will Infinity Pharmaceuticals (INFI) Report Negative Q4 Earnings? What You Should Know

Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

08:02 29 Mar 2024 INFI

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

11:17 29 Mar 2024 INFI

Down 44.4% in 4 Weeks, Here's Why Infinity (INFI) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Infinity (INFI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

11:24 29 Mar 2024 INFI

Infinity Pharmaceuticals, Inc. (INFI) Q3 2022 Earnings Call Transcript

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Jayne Kauffman - Senior Executive Coordinator Adelene Perkins - Chairman and Chief Executive Officer Robert Ilaria - Chief Medical Officer Larry Bloch - President Conference Call Participants Edward Tenthoff - Piper Sandler Soumit Roy - Jones Research Mayank Mamtani - B. Riley Operator Ladies and gentlemen, thank you for standing by.

08:25 29 Mar 2024 INFI

Infinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass.

11:03 29 Mar 2024 INFI

Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q2 2022 Results - Earnings Call Transcript

Start Time: 16:30 January 1, 0000 4:58 PM ET Infinity Pharmaceuticals, Inc. (NASDAQ:INFI ) Q2 2022 Earnings Conference Call August 09, 2022, 16:30 PM ET Company Participants Adelene Perkins - Chair and CEO Robert Ilaria - CMO Larry Bloch - President Jayne Kauffman - Senior Executive Coordinator Conference Call Participants Edward Tenthoff - Piper Sandler Robyn Karnauskas - Truist Securities Operator Ladies and gentlemen, thank you for standing by. Welcome to the Infinity Pharmaceuticals Conference Call to discuss the Company's Second Quarter 2022 Financial Results and Business Update.

08:35 29 Mar 2024 INFI

Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022. H.C. Wainwright Global Investment Conference Presentation (hybrid) Date: Tuesday, May 24th

INFI Financial details

Company Rating
Neutral
Market Cap
726.09K
Income
-39.91M
Revenue
2.57M
Book val./share
-0.42
Cash/share
0.2
Dividend
-
Dividend %
-
Employees
30
Optionable
No
Shortable
Yes
Earnings
13 Nov 2023
P/E
-0.02
Forward P/E
-
PEG
0.01
P/S
0.28
P/B
-0.02
P/C
0.04
P/FCF
-0.02
Quick Ratio
1.47
Current Ratio
1.65
Debt / Equity
-0.02
LT Debt / Equity
-
-
-
EPS (TTM)
-0.45
EPS next Y
-
EPS next Q
-
EPS this Y
-9.43%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
19.14%
Revenue last 5Y
-34.88%
Revenue Q/Q
-20.25%
EPS Q/Q
-8.33%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.2%
Inst Trans
0.01%
ROA
-188%
ROE
167%
ROC
-4.59%
Gross Margin
40%
Oper. Margin
-1637%
Profit Margin
-1553%
Payout
-
Shs Outstand
90.76M
Shs Float
81.91M
-
-
-
-
Target Price
-
52W Range
0.0056-1.3
52W High
-
52W Low
-
RSI
37
Rel Volume
0.62
Avg Volume
3.98M
Volume
2.48M
Perf Week
48.15%
Perf Month
-
Perf Quarter
-
Perf Half Y
-55.56%
-
-
-
-
Beta
1.38036
-
-
Volatility
0%, 0%
Prev Close
105.13%
Price
0.008
Change
110.53%

INFI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.40.050.030.020.03
Net income per share
-0.2-0.83-0.72-0.53-0.48
Operating cash flow per share
-0.09-0.73-0.6-0.47-0.48
Free cash flow per share
-0.09-0.77-0.6-0.47-0.48
Cash per share
1.060.740.570.940.43
Book value per share
0.950.14-0.380.25-0.21
Tangible book value per share
0.950.14-0.380.25-0.21
Share holders equity per share
0.950.14-0.380.25-0.21
Interest debt per share
00.090.430.020.01
Market cap
65.39M54.7M126.9M192.59M49.98M
Enterprise value
16.77M34.37M121.79M113.3M12.58M
P/E ratio
-5.81-1.16-2.96-4.24-1.16
Price to sales ratio
2.9517.9473.82103.6619.27
POCF ratio
-13.87-1.32-3.55-4.74-1.18
PFCF ratio
-13.87-1.25-3.55-4.74-1.18
P/B Ratio
1.257.08-5.528.93-2.62
PTB ratio
1.257.08-5.528.93-2.62
EV to sales
0.7611.2770.8560.984.85
Enterprise value over EBITDA
-1.43-0.75-3.2-2.54-0.28
EV to operating cash flow
-3.56-0.83-3.41-2.79-0.3
EV to free cash flow
-3.56-0.78-3.4-2.79-0.3
Earnings yield
-0.17-0.86-0.34-0.24-0.87
Free cash flow yield
-0.07-0.8-0.28-0.21-0.85
Debt to equity
00.3-1.020.07-0.05
Debt to assets
00.050.60.020.02
Net debt to EBITDA
4.140.450.131.780.83
Current ratio
7.754.63.266.192.96
Interest coverage
-128.27-17.82-15.75-250.46-249.13
Income quality
0.420.880.880.90.96
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.644.697.227.635.19
Research and developement to revenue
0.898.8915.5717.0312.5
Intangibles to total assets
00000
Capex to operating cash flow
00.06000
Capex to revenue
0-0.76-0.03-0.01-0.01
Capex to depreciation
0-10.63-0.09-0.02-0.04
Stock based compensation to revenue
0.160.70.851.451.4
Graham number
2.081.592.491.731.53
ROIC
-0.24-3.81-16.87-1.852.45
Return on tangible assets
-0.19-0.96-1.09-0.54-1.03
Graham Net
0.920.02-0.470.2-0.26
Working capital
52.1M34.88M24.97M68.97M26.67M
Tangible asset value
52.46M7.73M-22.99M21.57M-19.05M
Net current asset value
52.06M3.29M-26.29M19.05M-20.9M
Invested capital
00.3-1.020.07-0.05
Average receivables
00000
Average payables
828K1.41M2.3M2.65M3.36M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
6.33K80.961.05K756.071.03K
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.064.510.350.480.35
Inventory turnover
00000
ROE
-0.21-6.091.87-2.112.27
Capex per share
0-0.04000

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.010.010.010.010.01
Net income per share
-0.13-0.12-0.1-0.12-0.11
Operating cash flow per share
-0.12-0.11-0.1-0.14-0.09
Free cash flow per share
-0.12-0.11-0.1-0.14-0.09
Cash per share
0.630.530.430.290.2
Book value per share
-0.01-0.12-0.21-0.32-0.42
Tangible book value per share
-0.01-0.12-0.21-0.32-0.42
Share holders equity per share
-0.01-0.12-0.21-0.32-0.42
Interest debt per share
0.010.010.010.010.01
Market cap
56.17M106.38M49.98M14.31M18.88M
Enterprise value
11.52M60.25M12.58M-10.65M1.76M
P/E ratio
-1.17-2.52-1.42-0.34-0.47
Price to sales ratio
81.88149.4192.0419.5732.38
POCF ratio
-5.3-11.32-5.62-1.14-2.36
PFCF ratio
-5.3-11.32-5.63-1.14-2.36
P/B Ratio
-50.74-9.78-2.62-0.51-0.5
PTB ratio
-50.74-9.78-2.62-0.51-0.5
EV to sales
16.884.6223.17-14.573.02
Enterprise value over EBITDA
-0.97-5.59-1.320.93-0.18
EV to operating cash flow
-1.09-6.41-1.410.85-0.22
EV to free cash flow
-1.09-6.41-1.420.85-0.22
Earnings yield
-0.21-0.1-0.18-0.74-0.53
Free cash flow yield
-0.19-0.09-0.18-0.88-0.42
Debt to equity
-1.07-0.1-0.05-0.03-0.02
Debt to assets
0.020.020.020.030.03
Net debt to EBITDA
3.754.283.922.191.71
Current ratio
4.163.482.962.511.65
Interest coverage
-267.07-241.8-211.96-255.71-224.89
Income quality
0.880.880.961.140.8
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
5.094.925.148.136.44
Research and developement to revenue
12.8210.7612.828.0111.32
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
000.0300
Capex to depreciation
000.1600
Stock based compensation to revenue
1.191.291.882.431.47
Graham number
0.190.570.690.921.02
ROIC
-9.451.220.510.410.28
Return on tangible assets
-0.19-0.2-0.21-0.35-0.47
Graham Net
-0.07-0.17-0.26-0.36-0.45
Working capital
45.27M35.15M26.67M17.07M7.84M
Tangible asset value
-1.11M-10.87M-19.05M-28.32M-37.41M
Net current asset value
-3.35M-13.12M-20.9M-29.91M-38.73M
Invested capital
-1.07-0.1-0.05-0.03-0.02
Average receivables
00000
Average payables
1.91M1.88M3.18M3.17M1.72M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
394.13409.511.21K394.9384.03
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.230.220.070.230.23
Inventory turnover
00000
ROE
10.80.970.460.380.27
Capex per share
00000

INFI Frequently Asked Questions

What is Infinity Pharmaceuticals, Inc. stock symbol ?

Infinity Pharmaceuticals, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol INFI

What is Infinity Pharmaceuticals, Inc. stock quote today ?

Infinity Pharmaceuticals, Inc. stock price is $0.008 today.

Is Infinity Pharmaceuticals, Inc. stock public?

Yes, Infinity Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Check Those
Similar Market Cap